IB Lab has specialized in the field of artificial intelligence in the health care sector (Health-AI). FDA approval should enable the company to succeed in entering the American market in the coming year. IB Lab has developed a software solution contributing to the early detection and diagnosis of bone diseases with the help of artificial intelligence (AI) and machine learning (ML). On the basis of cost-effective, conventional X-rays, the software recognizes different stages of diseases on the basis of anatomical parameters analyzed in combination with the bone structure. In this way, the software supports doctors in making efficient and reliable diagnoses.
The areas of application for the software range from conventional orthopedics with the joints of the musculoskeletal system to issues in clinical traumatology. “We see enormous potential for our solutions, particularly in the USA, where doctors see a decisive advantage in applying such technologies, says Richard Ljuhar, Managing Director of IB Lab.